Leo Pharma is the new owner of Finacea

Leo-Pharma

News today that Bayer HealthCare is selling its prescription dermatology business to the unlisted Danish company Leo Pharma.

Leo Pharma now becomes an interesting company for rosacea sufferers given the prevalence and efficacy of both Finacea and Finacea Foam. The future of these products and any related funded research now rests with Leo Pharma.

LEO Pharma A/S to expand its lead in medical dermatology with acquisition of Bayer’s prescription dermatology unit

Ballerup, Denmark and Leverkusen, Germany July 31, 2018 – LEO Pharma and Bayer announced today, that LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit.

The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids with an annual turnover in 2017 of more than 280 million euros.

It will enable LEO Pharma to expand significantly in key markets worldwide and broaden its therapeutic areas.

Bayer’s global medical dermatology portfolio, which includes prescription treatment solutions for acne (Skinoren®), fungal skin infections (Travogen® and Travocort®) and rosacea (Finacea®), and a range of topical steroids (Advantan®, Nerisona®, and Desonate®), will add complementary treatment areas and strengthen the existing business of LEO Pharma worldwide, allowing the company to more than double sales in some markets.

The transaction does not include Bayer’s over-the-counter dermatology portfolio of brands such as Bepanthen® and Canesten® amongst others.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.